Aurinia Pharmaceuticals Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Aurinia Pharmaceuticals Inc. (AUPH) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$5.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $561.00K, a 91.05% decline year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$5.59M.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $13.12M, a 24.88% decline year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$641.00K.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$4.66M, a 134.92% decline from fiscal 2024.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $13.33M, a 9.68% increase from fiscal 2023.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $12.15M, a 715.16% increase from fiscal 2022.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $1.49M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $561.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$5.03M 10-Q · filed 2026-08-06 | $8.09M derived: sum of 3 quarters · filed 2026-08-06 | $7.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$5.59M 10-Q · filed 2026-05-07 | $7.53M derived: sum of 2 quarters · filed 2026-05-07 | $6.89M derived: sum of 3 quarters · filed 2026-05-07 | $13.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $13.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.48M derived: sum of 2 quarters · filed 2026-02-26 | $18.75M derived: sum of 3 quarters · filed 2026-08-06 | -$4.66M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$641.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $5.63M derived: sum of 2 quarters · filed 2026-08-06 | -$17.78M 10-Q · filed 2025-11-04 | -$308.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$17.14M 10-Q · filed 2026-08-06 | $333.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$23.41M 10-Q · filed 2026-05-07 | -$5.94M derived: sum of 2 quarters · filed 2026-05-07 | -$6.27M derived: sum of 3 quarters · filed 2026-05-07 | -$2.14M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $17.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $17.14M derived: sum of 2 quarters · filed 2026-02-26 | $21.27M derived: sum of 3 quarters · filed 2026-02-26 | $13.33M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$334.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.80M derived: sum of 2 quarters · filed 2025-11-04 | -$4.14M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $4.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$3.81M 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | -$7.94M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $12.15M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $1.49M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |